

ACORDA THERAPEUTICS INC
Form 8-K/A
June 21, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 19, 2011

Acorda Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

000-50513
(Commission
File Number)

13-3831168
(I.R.S. Employer
Identification No.)

15 Skyline Drive,
Hawthorne, NY
(Address of principal
executive offices)

10532
(Zip Code)

Registrant's telephone number, including area code: (914) 347-4300

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Explanatory Note

On April 21, 2011, Acorda Therapeutics, Inc. (the “Company”) filed a Current Report on Form 8-K with the Securities and Exchange Commission to report, among other things, the election of Peder K. Jensen, M.D., to the Board of Directors of the Company effective April 19, 2011 (the “Initial Form 8-K”). This Current Report on Form 8-K/A is being filed as required pursuant to Item 5.02(d)(3) of Form 8-K solely to update certain information reported under Item 5.02(d)(3) of the Initial Form 8-K.

Item Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
5.02

(d) On June 16, 2011, Dr. Jensen was appointed to the Compensation Committee of the Company’s Board of Directors.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Acorda Therapeutics, Inc.

June 21, 2011

By: /s/ David
Lawrence
Name: David
Lawrence
Title: Chief
Financial Officer